Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 4/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910194 | 1.00 | MAPT (0.36) | MAPTMMP12MMP2MMP3GABBR2 | |
| SCHEMBL26103565 | 0.89 | HTT (0.34) | CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL12787298 | 0.86 | TSHR (0.39) | MAPTCYP3A4KMT2ACYP2C19 | |
| SCHEMBL8952823 | 0.85 | MAPT (0.38) | MAPTMMP12MMP2MMP3GABBR2 | |
| SCHEMBL8952810 | 0.85 | MAPT (0.38) | MAPTMMP12MMP2MMP3GABBR2 | |
| SCHEMBL25175870 | 0.85 | MAPT (0.38) | MAPTMMP12MMP2MMP3GABBR2 | |
| SCHEMBL9828488 | 0.84 | MAPT (0.35) | MAPTMMP12MMP2MMP3GABBR2 | |
| SCHEMBL10433967 | 0.84 | MAPT (0.35) | MAPTMMP12MMP2MMP3GABBR2 | |
| SCHEMBL8953119 | 0.83 | MAPT (0.38) | MAPTMMP12MMP2MMP3GABBR2 | |
| SCHEMBL8953126 | 0.83 | MAPT (0.38) | MAPTMMP12MMP2MMP3GABBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065920-A1 | PROCESS FOR PREPARING PENTANOIC DIACID DERIVATIVES | RATIOPHARM GMBH (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2223909-A1 | Process for preparing pentanoic diacid derivatives | Ratiopharm GmbH (DE) | 2010-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065920-A1 | PROCESS FOR PREPARING PENTANOIC DIACID DERIVATIVES | HMGCR, DPYD, FDPS | MAPT 2399/4885MMP12 3662/4885MMP2 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.